Revelation Biosciences, Inc.

Stage 1 · Basing · week 1

As of Oct 22, 2026, Revelation Biosciences is in Stage 1, the basing phase, now in its first week (since Oct 21, 2026). It closed at $3.68, 31.3% below its 52-week high and above its 200-day average, which is falling.

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. More about the company

$3.68

+2.22% today

$2.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is REVB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 106w

S4 46w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 106w → S1 3w → S4 46w → S1 6w → S4 5w → S1 1w current

Total tracked: 166 weeks across 6 stage runs.

REVB among Biotechnology272nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…272	REVBRevelation Biosciences, Inc.	Stage 1 · wk 1	35	+294.0%

vs 52W High

-31.3%

$0.49 lo$5.36 hi

31.3% below 52W high, far from high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 1

1w13w26w

Week 1, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

179.2%

200 DMA: $1.32 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.63x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+294.0%

+247.2%

+217.2%

YTD

+13.2%

-26.4%

Scan Membership

Breakout Watch

Latest: 2021-10-25

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 1 · Vol 0.63x

2026-10-21S14→1

Wk 1 · Vol 0.34x

2026-10-20S4

Wk 5 · Vol 2.83x

2026-10-19S4

Wk 5 · Vol 6.23x

2026-10-16S4

Wk 5 · Vol 17.64x

2026-10-15S4

Wk 5 · Vol 0.57x

2026-10-14S4

Wk 4 · Vol 0.63x

2026-10-13S4

Wk 4 · Vol 0.74x

2026-10-12S4

Wk 4 · Vol 0.34x

2026-10-09S4

Wk 4 · Vol 0.68x

2026-10-08S4

Wk 4 · Vol 1.79x

2026-10-07S4

Wk 3 · Vol 1.44x

Moving averages & range

50 DMA

$1.13

200 DMA

$1.32

52W High

$5.36

52W Low

$0.49

5D Low

$0.49

Resistance levels (recent highs)

20d High

$3.70

60d High

$3.70

120d High

$3.70

250d High

$5.36

Next resistance

+0.5%

to 20d High

P/E (TTM)

0.1

Forward -0.2

ROE

-154.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

Revelation Biosciences: quick answers

What stage is Revelation Biosciences in?

As of Oct 22, 2026, Revelation Biosciences (REVB) is in Stage 1, the basing phase. It entered Stage 1 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Revelation Biosciences in an uptrend?

Not yet. Revelation Biosciences is in Stage 1, a base that can come before an uptrend. It trades 179.2% above its 200-day average, which is falling.

How far is Revelation Biosciences from its 52-week high?

Revelation Biosciences closed at $3.68 on Oct 22, 2026, 31.3% below its 52-week high of $5.36. Its 52-week low is $0.49.

How has Revelation Biosciences performed over the past year?

As of Oct 22, 2026, Revelation Biosciences is down 26.4% over the past year and up 13.2% so far in 2026.

Which sector and industry is Revelation Biosciences in?

Revelation Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.